The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Amgen discovers, develops, manufactures and delivers innovative human therapeutics, announced new long-term data showing that Prolia (denosumab) treatment for up to eight years in post-menopausal ...
Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
THOUSAND OAKS, Calif., June 1, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from a randomized, double-blind, placebo-controlled, multicenter Phase 3 study evaluating the treatment ...
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability ...
THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Amgen Inc. is conducting a Phase 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results